Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia in the Western world.1,2 In the UK, CLL accounts for 1% of all new cancer cases and 38% of all leukaemias.3
The new CLL Knowledge Centre provides healthcare professionals with important information to aid the treatment and management of patients with the disease. Content is arranged within three main areas: ‘Disease awareness’, ‘Events’ and ‘Resources’.
Healthcare professionals will find sections on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment, management, an upcoming events calendar and useful external links.
We are conducting a short survey regarding educational needs of healthcare professionals in relation to chronic lymphocytic leukaemia (CLL) and other haematological malignancies.
The questions will take approximately 5-10 minutes of your time to complete and your input will be much appreciated.
Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013 Nov 28;122(23):3723-34.
Gibson J, Iland HJ, Larsen SR, Brown CM, Joshua DE. Leukaemias into the 21st century. Part 2: the chronic leukaemias. Intern Med J. 2013 May;43(5):484-94.
Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men,1 making it a major cause of morbidity. Risk factors for prostate cancer include, increasing age, genetic susceptibility, glucose intolerance and environmental factors.2
The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
Tewari R, Rajender S, Natu SM et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763-776.
Soft Tissue Sarcomas (STS) are malignant (cancerous) tumors that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons (bands of fiber that connect muscles to bones), fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue.
Management of soft tissue sarcoma depends on the stage of disease and histological subtype.1 Surgery is the mainstay of treatment for patients with localised disease and is often curative. However, as recurrence is likely to occur when tumour cells remain after surgery, adjuvant radiotherapy is often also considered, especially for patients with intermediate or high-grade tumours. Radiotherapy, uses high energy rays to help cure cancers, is also often administered for patients in whom surgery is inappropriate or who decline surgery.1
For soft tissue sarcomas, the specialist healthcare professional may recommend radiotherapy to shrink sarcomas before surgery, help stop the sarcoma returning after surgery, to help slow the growth rate of advanced sarcomas and help relieve symptoms.
Discover classification of sarcomas by histopathology, look at prevalence and more by visiting the The Soft Tissue Sarcoma Knowledge Centre.
. Clark MA, Fisher C et al. (2005) “Soft-tissue sarcomas in adults.” N Engl JMed 353(7): 701–11.
The Anti-Infectives Knowledge Network – Clostridium difficile infections (AIKN-CDI), an initiative by Astellas Pharma EMEA, shares the expertise and experience of thought leaders in the area of anti-infectives.
Opportunity to participate in the second round of the largest ever clinician consensus report through completing a questionnaire. Subsequent recommendations will be made based on the data collected from this questionnaire
Please remember to return often to read updated news, clinical insights, and essential information from the latest congresses.
The Anti-Infectives Knowledge Network – Invasive Fungal Infections (AIKN-IFI), an initiative by Astellas Pharma EMEA, assembles the experience and expertise of a number of thought leaders in the area of anti-infectives, with particular focus on invasive fungal infections.
This free resource is regularly updated with congress highlights, industry reports, policy changes, clinical guidelines and downloadable material (e.g. presentation slides) from major medical events.
The latest update to the AIKN-IFI is a summary of recent ESCMID-led recommendations into the prevention and management of infections in solid organ transplantation. These new recommendations are available in the guidelines section.
Oni Choudhury,Guy's and St Thomas' NHS Foundation Trust, London, UK Richard Leach,Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
Case History A 62-year-old woman presented with a 2-3-month history of breathlessness, non-productive cough, weight loss, lethargy and ankle oedema. Her exercise tolerance was limited to 50 yards by breathlessness.
Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK
Case History A 24-year-old woman was seen in the chest clinic with an eight-week history of cough with occasional sputum, fever and malaise. She also described an occasional nagging pain under her sternum and palpitations.
This guideline updates and replaces NICE clinical guideline CG27 (published June 2005). It offers..
... evidence-based advice on the recognition of and referral for suspected cancer in children, young people and adults.
This guideline covers the recognition and selection for referral or investigation in primary care of people of all ages, including children and young people, who may have cancer. Although we have used the terms 'men' and 'women' for recommendations on gender-related cancers, these recommendations also extend to people who have changed or are in the process of changing gender, and who retain the relevant organs.
The guideline aims to help people understand what to expect if they have symptoms that may suggest cancer. It should also help those in secondary care to understand which services should be provided for people with suspected cancer. Finally, these recommendations are recommendations, not requirements, and they are not intended to override clinical judgement.
The recommendations in this guideline have been organised into 3 separate sections to help clinicians find the relevant information easily. In the first, the recommendations are organised by cancer site. There is a section covering patient support, safety netting and the diagnostic process. Then, for those wanting to find recommendations on specific symptoms and primary care investigations, the recommendations are in a section organised by symptoms and investigation findings.
NICE has not recommended the PROGENSA PCA3 assay and the Prostate Health Index for use in people..
... having investigations for suspected prostate cancer, who have had a negative or inconclusive transrectal ultrasound prostate biopsy. The PCA3 assay is diagnostic test that detects the level of prostate cancer gene 3 (PCA3) in urine, and the PHI is a diagnostic test that detects the level of prostate-specific antigen (PSA) in blood.
Learning outcomes: 1) Recognize who is at risk of prostate cancer; 2) Review the current recommendations on prostate cancer screening; 3) Recognize the harms associated with prostate cancer biopsy; 4)...